What is Zacks Research’s Estimate for COCP FY2026 Earnings?

Cocrystal Pharma, Inc. (NASDAQ:COCP) – Zacks Research reduced their FY2026 earnings per share (EPS) estimates for Cocrystal Pharma in a note issued to investors on Monday, June 1st. Zacks Research analyst D. Bautz now forecasts that the company will post earnings per share of ($0.76) for the year, down from their prior forecast of ($0.73). The consensus estimate for Cocrystal Pharma’s current full-year earnings is ($0.67) per share.

Cocrystal Pharma (NASDAQ:COCP) last posted its quarterly earnings results on Friday, May 15th. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02). The business had revenue of $0.23 million during the quarter, compared to analyst estimates of $0.23 million.

Separately, Weiss Ratings cut Cocrystal Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, May 22nd. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $6.00.

Cocrystal Pharma Stock Down 5.4%

NASDAQ:COCP opened at $1.05 on Wednesday. The business’s 50-day simple moving average is $1.29 and its two-hundred day simple moving average is $1.11. The stock has a market cap of $14.48 million, a PE ratio of -1.44 and a beta of 1.42. Cocrystal Pharma has a 52 week low of $0.86 and a 52 week high of $2.67.

Institutional Investors Weigh In On Cocrystal Pharma

A hedge fund recently bought a new stake in Cocrystal Pharma stock. DRW Securities LLC bought a new position in Cocrystal Pharma, Inc. (NASDAQ:COCP) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 33,593 shares of the company’s stock, valued at approximately $33,000. DRW Securities LLC owned about 0.24% of Cocrystal Pharma at the end of the most recent quarter. Institutional investors and hedge funds own 6.72% of the company’s stock.

About Cocrystal Pharma

Cocrystal Pharma, Inc (NASDAQ:COCP) is a clinical-stage biotechnology company focused on the discovery and development of novel antiviral therapeutics. Utilizing an integrated structure-guided drug design platform, the company combines x-ray crystallography, computational chemistry and medicinal chemistry to identify and optimize small molecule inhibitors targeting key viral enzymes. This approach is intended to accelerate the progression of lead candidates from discovery through preclinical development.

The company’s pipeline includes multiple preclinical programs aimed at treating respiratory and systemic viral infections.